Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group

scientific article published on August 1, 2003

Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0093-7754(03)00400-7
P953full work available at URLhttps://api.elsevier.com/content/article/PII:S0093775403004007?httpAccept=text/plain
https://api.elsevier.com/content/article/PII:S0093775403004007?httpAccept=text/xml
P698PubMed publication ID14523790

P50authorDavid R GandaraQ73567194
Timothy SynoldQ78536675
Heinz-Josef LenzQ89668545
P2093author name stringAnne Hamilton
Percy Ivy
Heinz Josef Lenz
Sridhar Mani
David Gandara
Sunil Sharma
Martin Graham
Chris H. Takimoto
Ramesh K. Ramanathan
Daniel Mulkerin
Jeffrey Longmate
James H. Doroshow
Scot C. Remick
P433issue4 Suppl 15
P407language of work or nameEnglishQ1860
P921main subjectpharmacologyQ128406
oncologyQ162555
oxaliplatinQ422327
P304page(s)14-19
P577publication date2003-08-01
P1433published inSeminars in OncologyQ14330412
P1476titlePharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group
P478volume30

Reverse relations

cites work (P2860)
Q33373035A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression
Q35906940A review of oxaliplatin and its clinical use in colorectal cancer
Q37475755Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction
Q38626963Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer
Q35680674Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer
Q37682504Clinical management of inflammatory bowel disease in the organ recipient
Q36459787Clinical pharmacology of cancer therapies in older adults.
Q38241395Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.
Q38101612Current opinion on optimal treatment for colorectal cancer.
Q35827606Drug development in oncology: classical cytotoxics and molecularly targeted agents
Q36165081Efficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma: A meta-analysis of prospective studies
Q37419104Gefitinib, Fluorouracil, Oxaliplatin, and Leucovorin (IFOX) Regimen for Colorectal Cancer
Q26861560Hepatotoxicity Secondary to Chemotherapy
Q37126758Incidence and management of colorectal cancer in liver transplant recipients
Q36788436Oxaliplatin in the treatment of colorectal cancer
Q37326848Part I: Liver function in oncology: biochemistry and beyond
Q37336474Part II: Liver function in oncology: towards safer chemotherapy use.
Q36715263Pharmacokinetics of chemotherapy in the older patient.
Q42364212Safe use of capecitabine-cisplatin in metastatic gastric carcinoma with severe liver dysfunction: a case report from Algeria
Q46024262Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer.
Q38866096The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects
Q38030767Treatment decisions for elderly patients with haematological malignancies: a dilemma